5 active not recruiting, 3 recruiting, 1 not yet recruiting. 9 Phase 3.
By phase and status
Follow giredestrant: new trials by email Literature Review of giredestrant trials Research Report on giredestrant
Trials (filtered) newest first · largest first
All 9 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer Atirmociclib, giredestrant, Atirmociclib placebo - Early Breast Cancer, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) | Phase 3 | Not yet recruiting | 3800 | 2026-12-01 | 2026-11-10 |
A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment Giredestrant - Early Breast Cancer, Estrogen Receptor-Positive Breast Cancer | Phase 3 | Recruiting | 1500 | 2026-11-30 | 2026-11-12 |
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer) Giredestrant - Early Breast Cancer | Phase 3 | Recruiting | 300 | 2026-08-25 | 2026-11-12 |
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) Giredestrant, Fulvestrant, Abemaciclib - Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | Phase 3 | Active not recruiting | 1050 | 2023-12-11 | 2026-09-14 |
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study Ipatasertib, Tiragolumab, Atezolizumab - Cancer | Phase 3 | Recruiting | 200 | 2023-06-01 | 2026-11-06 |
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) Giredestrant, Exemestane, Fulvestrant - Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer | Phase 3 | Active not recruiting | 373 | 2022-08-03 | 2026-11-03 |
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) Phesgo, Giredestrant, Docetaxel - Locally Advanced or Metastatic Breast Cancer | Phase 3 | Active not recruiting | 922 | 2022-07-18 | 2026-10-02 |
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) Giredestrant, Physician's Choice of Endocrine Therapy, LHRH Agonist - Early Breast Cancer | Phase 3 | Active not recruiting | 4170 | 2021-08-27 | 2026-10-15 |
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) Giredestrant, Giredestrant-matched Placebo, Letrozole - Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | Phase 3 | Active not recruiting | 992 | 2020-10-09 | 2026-11-12 |
Conditions studied
Breast Neoplasms (7) · Neoplasms (1)
Sponsors
Hoffmann-La Roche (6) · Genentech, Inc. (2) · Pfizer (1)
Countries
United States (7) · South Korea (6) · Taiwan (6) · Argentina (5) · Belgium (5) · Canada (5) · China (5) · France (5) · Germany (5) · Greece (5) · Italy (5) · Mexico (5) · Poland (5) · Spain (5) · Thailand (5)
Results publications
PMID 38789924, PMID 42814929
NIH funding
2023 (4)